Skip to main navigation Skip to search Skip to main content

The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R

  • David J. Gross*
  • , Gabriel Munter
  • , Menachem Bitan
  • , Tali Siegal
  • , Alberto Gabizon
  • , Ronny Weitzen
  • , Ofer Merimsky
  • , Aliza Ackerstein
  • , Asher Salmon
  • , Avishai Sella
  • , Shimon Slavin
  • *Corresponding author for this work
  • Hadassah University Medical Centre
  • Shaare Zedek Medical Center
  • Sheba Medical Center at Tel Hashomer
  • Tel Aviv Sourasky Medical Center
  • Assaf Harofeh Medical Center

Research output: Contribution to journalArticlepeer-review

132 Scopus citations

Fingerprint

Dive into the research topics of 'The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science